Non-inferiority trials

被引:1
|
作者
Elie, Caroline [1 ]
Touze, Emmanuel [2 ]
机构
[1] Univ Paris 05, Fac Med, EA 4472, Hop Necker Enfants Malad,Serv Biostat & Informat, F-75015 Paris, France
[2] Univ Paris 05, Inserm UMR S894, Hop St Anne, Serv Neurol, F-75014 Paris, France
来源
SANG THROMBOSE VAISSEAUX | 2012年 / 24卷 / 02期
关键词
randomized controlled trial; non-inferiority trial; confidence intervals; EQUIVALENCE RANDOMIZED-TRIALS; CONSORT STATEMENT; NONINFERIORITY;
D O I
10.1684/stv.2012.0682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-inferiority trials In many diseases, effective treatments are already available. Thus, expected benefits with new treatments in development are often small. In this context, the statistical demonstration of superiority of these new treatments is often difficult even impossible to be proven. Consequently, many current trials aim to show that a new treatment is safer and/or easy to use without loss of efficacy, rather than to demonstrate superiority. Such trials, called "non-inferiority" trials, need be distinguished from superiority trials regarding both methodological and statistical aspects. In this note, we examine the statistical rationale and methodological features of non-inferiority trials. We present analysis methods using confidence intervals approach and key aspects of their design. Finally, we consider the possibility to switch from non-inferiority to superiority testing.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 50 条
  • [31] Applying the Estimand Framework to Non-Inferiority Trials
    Lynggaard, Helle
    Keene, Oliver N.
    Muetze, Tobias
    Rehal, Sunita
    [J]. PHARMACEUTICAL STATISTICS, 2024,
  • [32] An evidential approach to non-inferiority clinical trials
    Wang, Sue-Jane
    Blume, Jeffrey D.
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (05) : 440 - 447
  • [33] Strength of evidence of non-inferiority trials-The adjustment of the type I error rate in non-inferiority trials with the synthesis method
    Kang, Seung-Ho
    Tsong, Yi
    [J]. STATISTICS IN MEDICINE, 2010, 29 (14) : 1477 - 1487
  • [34] Two-stage winner designs for non-inferiority trials with pre-specified non-inferiority margin
    Wang, Pin-Wen
    Lu, Shou-En
    Lin, Yong
    Shih, Weichung J.
    Lan, K. K. Gordon
    [J]. JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2017, 183 : 44 - 61
  • [35] Non-adherence in non-inferiority trials: pitfalls and recommendations
    Mo, Yin
    Lim, Cherry
    Watson, James A.
    White, Nicholas J.
    Cooper, Ben S.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
  • [36] Emergent HIV Brug resistance in non-inferiority trials
    Ripamonti, Diego
    Zazzi, Maurizio
    [J]. LANCET HIV, 2023, 10 (10): : E632 - E634
  • [37] Adaptive Non-inferiority Margins in HIV Prevention Trials
    Hanscom, Brett
    Williamson, Brian
    Hughes, James
    Donnell, Deborah
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 103 - 103
  • [38] Bio-creep in non-inferiority clinical trials
    Everson-Stewart, Siobhan
    Emerson, Scott S.
    [J]. STATISTICS IN MEDICINE, 2010, 29 (27) : 2769 - 2780
  • [39] Non-inferiority margins employed in clinical trials in Japan
    Gosho, M.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (03) : 289 - 298
  • [40] Bayesian approach to non-inferiority trials for normal means
    Gamalo, M. Amper
    Wu, Rui
    Tiwari, Ram C.
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2016, 25 (01) : 221 - 240